Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain

PLoS ONE

Volumn 13, Issue 8, 2018, Pages

  Purriños Hermida, M Jesus ^a   Santiago Pérez, María Isolina ^a   Treviño, Mercedes ^b   Dopazo, Rafaela ^b   Cañizares, Angelina ^c   Bonacho, Isolina ^c   Trigo, Matilde ^d   Fernández, M Eva ^d   Cid, Ana ^e   Gómez, David ^e   Ordóñez, Patricia ^f   Coira, Amparo ^g   Armada, M J ^h   Porto, Magdalena ⁱ   Perez, Sonia ^i,j   Malvar Pintos, Alberto ^a  

^a Dirección Xeral de Saúde Pública   (Spain)

^b University Hospital of Santiago de Compostela   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d University Hospital of Pontevedra   (Spain)

^e University Hospital of Ourense   (Spain)

^f Universidad de La Coruña   (Spain)

^g Pneumology Unit   (Spain)

^h Fingoi Health CareCentre   (Spain)

ⁱ University Hospital of Vigo   (Spain)

^j Rare Diseases and Pediatric Medicine Research Group   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADULT; AGE; ARTICLE; BEHAVIOR CHANGE; DRUG EFFICACY; FEMALE; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; INTERMETHOD COMPARISON; PREVALENCE; QUESTIONNAIRE; SEXUAL BEHAVIOR; SEXUAL INTERCOURSE; SPAIN; UTERINE CERVIX BIOPSY; VACCINATION; VIRUS DETECTION; WART VIRUS; WOMEN'S HEALTH; ALPHAPAPILLOMAVIRUS; CASE CONTROL STUDY; CLASSIFICATION; DIAGNOSTIC KIT; GENETICS; GENOTYPING TECHNIQUE; ISOLATION AND PURIFICATION; MASS IMMUNIZATION; PAPILLOMAVIRUS INFECTION; PREGNANCY; PROCEDURES; PROGRAM EVALUATION; YOUNG ADULT;

ADULT; ALPHAPAPILLOMAVIRUS; CASE-CONTROL STUDIES; FEMALE; GENOTYPING TECHNIQUES; HUMANS; MASS VACCINATION; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREGNANCY; PREVALENCE; PROGRAM EVALUATION; REAGENT KITS, DIAGNOSTIC; SEXUAL BEHAVIOR; SPAIN; SURVEYS AND QUESTIONNAIRES; YOUNG ADULT;

EID: 85051329112     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0201653     Document Type: Article

References (22)

1. World Health Organization. Cervical cancer, human papillomavirus (HPV), and HPV vaccines—Key points for policy-makers and health professionals [Internet]. WHO Press, World Health Organization; 2007. Available: http://apps.who.int/iris/bitstream/10665/69873/1/WHO_RHR_08.14_eng.pdf
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005; 55: 74–108. PMID: 15761078
3. Insinga RP, Liaw K-L, Johnson LG, Madeleine MM. A systematic review of the prevalence and attribution of human papillomavirus types among cervical, vaginal, and vulvar precancers and cancers in the United States. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1611–1622. https://doi.org/10.1158/10559965.EPI-07-2922 PMID: 18628412
4. Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012; 30 Suppl 5: F12–23. https://doi.org/10.1016/j.vaccine.2012.07.055 PMID: 23199955
5. Bruni L, Barrionuevo-Rosas L, Albero G, Serrano B, Mena M, Gómez D, et al. Human Papillomavirus and Related Diseases in the World. Summary Report 27 July 2017 [Internet]. ICO Information Centre on HPV and Cancer (HPV Information Centre); 2017. Available: http://www.hpvcentre.net/statistics/reports/XWX.pdf
6. Lehtinen M, Paavonen J, Wheeler CM, Jaisamrarn U, Garland SM, Castellsagué X, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol. 2012; 13: 89–99. https://doi.org/10.1016/S1470-2045(11)70286-8 PMID: 22075171
7. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in EU countries–an update [Internet]. Stockholm: ECDC; 2012. Available: https://ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/20120905_GUI_HPV_vaccine_update.pdf
8. Garland SM, Kjaer SK, Muñoz N, Block SL, Brown DR, DiNubile MJ, et al. Impact and Effectiveness of the Quadrivalent Human Papillomavirus Vaccine: A Systematic Review of 10 Years of Real-world Experience. Clin Infect Dis. 2016; 63: 519–527. https://doi.org/10.1093/cid/ciw354 PMID: 27230391
9. Huh WK, Joura EA, Giuliano AR, Iversen O-E, de Andrade RP, Ault KA, et al. Final efficacy, immunoge-nicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial. The Lancet. 2017; 390: 2143–2159. https://doi.org/10.1016/S0140-6736(17)31821-4
10. Trigo-Daporta M, García-Campello M, Pérez-Ríos M, Santiago-Pérez MI, Fernandez-Rodriguez E, Guinarte G, et al. High-risk human papillomavirus in Galicia, Spain: prevalence and evaluation of the sample representativeness. Scand J Infect Dis. 2014; 46: 737–744. https://doi.org/10.3109/00365548.2014.930966 PMID: 25189272
11. Mesher D, Soldan K, Howell-Jones R, Panwar K, Manyenga P, Jit M, et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine. 2013; 32: 26–32. https://doi.org/10.1016/j.vaccine.2013.10.085 PMID: 24211166
12. Markowitz LE, Hariri S, Lin C, Dunne EF, Steinau M, McQuillan G, et al. Reduction in Human Papillomavirus (HPV) Prevalence Among Young Women Following HPV Vaccine Introduction in the United States, National Health and Nutrition Examination Surveys, 2003–2010. J Infect Dis. 2013; 208: 385–393. https://doi.org/10.1093/infdis/jit192 PMID: 23785124
13. Royston P. Multiple imputation of missing values: update of ice. Stata J. 2005; 5: 527–536.
14. Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV After Introduction of the Vaccination Program in the United States. Pediatrics. 2016; 137: e20151968. https://doi.org/10.1542/peds.2015-1968 PMID: 26908697
15. Kavanagh K, Pollock KGJ, Potts A, Love J, Cuschieri K, Cubie H, et al. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer. 2014; 110: 2804–2811. https://doi.org/10.1038/bjc.2014.198 PMID: 24736582
16. Cameron RL, Kavanagh K, Pan J, Love J, Cuschieri K, Robertson C, et al. Human Papillomavirus Prevalence and Herd Immunity after Introduction of Vaccination Program, Scotland, 2009–2013. Emerging Infect Dis. 2016; 22: 56–64. https://doi.org/10.3201/eid2201.150736 PMID: 26692336
17. Tabrizi SN, Brotherton JML, Kaldor JM, Skinner SR, Liu B, Bateson D, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis. 2014; 14: 958–966. https://doi.org/10.1016/S1473-3099(14) 70841-2 PMID: 25107680
18. Bissett SL, Godi A, Jit M, Beddows S. Seropositivity to non-vaccine incorporated genotypes induced by the bivalent and quadrivalent HPV vaccines: A systematic review and meta-analysis. Vaccine. 2017; 35: 3922–3929. https://doi.org/10.1016/j.vaccine.2017.06.028 PMID: 28633892
19. Kemp TJ, Hildesheim A, Safaeian M, Dauner JG, Pan Y, Porras C, et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine. 2011; 29: 2011–2014. https://doi.org/10.1016/j.vaccine.2011.01.001 PMID: 21241731
20. Drolet M, Bénard É, Boily M-C, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015; 15: 565–580. https://doi.org/10.1016/S1473-3099(14)71073-4 PMID: 25744474
21. Kreimer AR, Struyf F, Del Rosario-Raymundo MR, Hildesheim A, Skinner SR, Wacholder S, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA Trials. Lancet Oncol. 2015; 16: 775–786. https://doi.org/10.1016/S1470-2045(15)00047-9 PMID: 26071347
22. Phillips S, Cornall AM, Machalek DA, Garland SM, Bateson D, Garefalakis M, et al. Comparison of the Roche Cobas® 4800 HPV assay to Roche Amplicor for detection of high-risk human papillomavirus. Eur J Clin Microbiol Infect Dis. 2016; 35: 1305–1307. https://doi.org/10.1007/s10096-016-2665-1PMID: 27177752